Assessment of Platelet Function in the Hemostasis System in Women with Premature Ovarian Insufficiency
Keywords:
Premature ovarian insufficiency (POI), Platelet dysfunction, Consumption, thrombocytopathy, Hemostasis systemAbstract
Premature ovarian insufficiency (POI) is a polyetiological condition characterized by the cessation of ovarian function before the age of 40, significantly impacting women's quality of life. This study investigates the platelet component of the hemostasis system in 35 women with POI compared to 50 age-matched women with normal ovarian function. Results indicate the presence of consumption thrombocytopathy in women with POI, with a significant reduction in platelet count (p<0.01) and decreased aggregation activity, particularly in secondary aggregation (p<0.01). Collagen-induced platelet aggregation was also impaired, with a twofold prolongation of the latent phase (p<0.01). These changes reflect hyperactive yet dysfunctional platelets, contributing to a pre-thrombotic state in women with POI. The study highlights the need for early interventions to correct endothelial and hemostatic imbalances in patients receiving hormone replacement therapy (HRT) for POI. Timely therapeutic strategies could mitigate the progression to thrombotic complications, improving overall health outcomes and quality of life for these patients.
References
Barrett-Connor, E. (2013). Menopause, atherosclerosis, and coronary artery disease. Current opinion in pharmacology, 13(2), 186-191.
Eshre Guideline Group on POI, Webber, L., Davies, M., Anderson, R., Bartlett, J., Braat, D., ... & Vermeulen, N. (2016). ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction, 31(5), 926-937.
Ibragimov, K. I. (2022). The risk of cardiovascular disease in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a clinic based case control study. Journal of Global Health Reports, 4(2).
Ibragimov, K., Sultonov, I., & Ravshanova, M. (2024). The Effectiveness of the Combination Therapy with biologic DMARDS in Rheumatoid Arthritis. Frontiers of Global Science, 2(1), 17-24.
Ibragimov, K., Sultonov, I., & Ravshanova, M. (2024). The Effectiveness of the Combination Therapy with biologic DMARDS in Rheumatoid Arthritis. Frontiers of Global Science, 2(1), 17-24.
Jang, H., Hong, K., & Choi, Y. (2017). Melatonin and fertoprotective adjuvants: prevention against premature ovarian failure during chemotherapy. International journal of molecular sciences, 18(6), 1221.
Laven, J. S. (2016, July). Primary ovarian insufficiency. In Seminars in reproductive medicine (Vol. 34, No. 04, pp. 230-234). Thieme Medical Publishers.
Neumannová, H., & Müllerová, M. (2018). Premature ovarian failure. Casopis Lekaru Ceskych, 157(7), 350-353.
Newson, L. R., & Lewis, R. (2018). Premature ovarian insufficiency: why is it not being diagnosed enough in primary care?. British Journal of General Practice, 68(667), 83-83.
North American Menopause Society. (2010). Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause (New York, NY), 17(2), 242-255.
Papagianni, V., Deligeoroglou, E., Makrakis, E., Botsis, D., & Creatsas, G. (2011). Response to hormonal treatment of young females with primary or very premature ovarian failure. Gynecological Endocrinology, 27(5), 291-299.
Podfigurna, A., & Męczekalski, B. (2018). Cardiovascular health in patients with premature ovarian insufficiency. Management of long-term consequences. Menopause Review/Przegląd Menopauzalny, 17(3), 109-111.
Tashinova, L., Khamraeva, N., Mambetova, L., Khasanov, F., & Ibragimov, K. (2023). Risk factors for the development of systemic lupus erythematosus (sle) in asians: a research case-control. In BIO Web of Conferences (Vol. 65, p. 05017). EDP Sciences.
